• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Amryt Pharma plc

    4/12/23 8:20:17 AM ET
    $AMYT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMYT alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-39365
    Issuer: Amryt Pharma plc
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: Dept 920a 196 High Road
    Wood Green
    London UNITED KINGDOM N22 8HH
    Telephone number: +442030267257
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    American Depositary Shares
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-04-12 By Tara Petta Vice President
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AMYT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMYT

    DatePrice TargetRatingAnalyst
    9/6/2022$19.00Buy
    Canaccord Genuity
    3/10/2022$20.00 → $18.00Buy
    HC Wainwright & Co.
    3/10/2022$9.00 → $10.00Outperform
    SVB Leerink
    11/23/2021$23.00 → $19.00Outperform
    SVB Leerink
    10/4/2021$45.00Buy
    JonesTrading
    8/19/2021$22.00Outperform
    SVB Leerink
    8/19/2021$22.00Outperform
    Cowen
    7/27/2021$29.00Buy
    H.C. Wainwright
    More analyst ratings

    $AMYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)

      SC 13G/A - Amryt Pharma plc (0001783010) (Subject)

      4/18/23 4:15:50 PM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)

      SC 13G/A - Amryt Pharma plc (0001783010) (Subject)

      2/13/23 10:24:07 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)

      SC 13G/A - Amryt Pharma plc (0001783010) (Subject)

      2/10/23 4:00:19 PM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMYT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc

      ●  Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. PARMA, Italy, DUBLIN and BOSTON, MA, April 12, 2023 /PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to ra

      4/12/23 7:58:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc

      Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our comp

      4/12/23 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • High Court of Justice of England and Wales Sanctions Scheme of Arrangement

      High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that the High Court of Justice of England and Wales (the "Court") has sanctioned the scheme of arrangement providing for the proposed acquisition (the "Transaction") of Amryt by Chiesi Farmaceutici S.p.A. ("Chiesi") at a hearing held on March 31, 2023. The parties expect the closing of the Transa

      4/3/23 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMYT
    Leadership Updates

    Live Leadership Updates

    See more
    • Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

      Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr Tracy Cunningham as Chief Medical officer (CMO) with immediate effect. Dr Cunningham joined Amryt in April 2020 as VP, Head of Development with responsibility for pre-clinical and clinical development of the Amryt portfolio. Prior to this, she held senior regional and global leadership roles in AstraZeneca, Novartis and GlaxoSmithKine. She is a graduate of the Roya

      6/27/22 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amryt Announces the Appointment of Sheila Frame as President Americas

      DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Sheila Frame as President Americas. Sheila will lead all aspects of product commercialization for Amryt in the Americas.  Sheila has held senior leadership roles across several specialty areas with Novartis, Bristol-Myers Squibb, UCB, and AstraZeneca and has worked and lived in North America and in Europe.  Sheila holds an MBA from Concordia University. Dr Joe Wiley, CEO of Amryt Pharma, commented: “Sheila is a very experienced

      4/6/21 2:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity resumed coverage on Amryt Pharma plc with a new price target

      Canaccord Genuity resumed coverage of Amryt Pharma plc with a rating of Buy and set a new price target of $19.00

      9/6/22 8:49:27 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Amryt Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Amryt Pharma with a rating of Buy and set a new price target of $18.00 from $20.00 previously

      3/10/22 6:17:28 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Amryt Pharma with a new price target

      SVB Leerink reiterated coverage of Amryt Pharma with a rating of Outperform and set a new price target of $10.00 from $9.00 previously

      3/10/22 4:40:51 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMYT
    SEC Filings

    See more
    • SEC Form EFFECT filed by Amryt Pharma plc

      EFFECT - Amryt Pharma plc (0001783010) (Filer)

      4/24/23 12:15:24 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15F-12B filed by Amryt Pharma plc

      15F-12B - Amryt Pharma plc (0001783010) (Filer)

      4/24/23 6:00:57 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Amryt Pharma plc

      EFFECT - Amryt Pharma plc (0001783010) (Filer)

      4/24/23 12:15:20 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMYT
    Financials

    Live finance-specific insights

    See more
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt to Report Q3 2022 Results on November 3, 2022

      Amryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the third quarter 2022 will be released on Thursday, November 3, 2022 at 0700 ET/1100 GMT. Amryt will host a conference call and webcast for analysts and investors on November 3, 2022 at 0830 ET/1230 GMT. Webcast Player URL: https://edge.media-server.com/mmc/p/6nxxorrj Telephone Dial in details: Standard International Number + 39 (0) 02 802 0911 United States +1

      10/19/22 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals